WHO ICTRP trial
A Phase II study of carfilzomib, oral cyclophosphamide, and dexamethasone for…
KCT0008537 · Clinical Research Information Service (CRIS) · Not Recruiting
Key facts
| Trial ID | KCT0008537 |
|---|---|
| Public title | A Phase II study of carfilzomib, oral cyclophosphamide, and dexamethasone for relapsed and/or refractory multiple myeloma |
| Scientific title | A Phase II study of carfilzomib, oral cyclophosphamide, and dexamethasone for relapsed and/or refractory multiple myeloma |
| Primary sponsor | Dong-A University Hospital |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Not Recruiting |
| Study type | Interventional Study |
| Phase | Phase2 |
| Countries | Korea, Republic of |
| Conditions | Neoplasms |
| Interventions | Drug : Carfilzomib, 70 mg/m2 IV 1), 2) - Day 1, 8, 15 Cyclophosphamide, 50 mg PO - Day 1-21 Dexamethasone 40mg IV or 19.5mg BID PO - Day 1, 8, 15, 22 1) On the first day of cycle 1, 20 mg/m2 is administered. 2) Administer intravenously over… |
| Registration date | Jun 20, 2023 |
| Target size | 49 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: